CLVS1 Antibody - #DF15830

(1)   (3)  
Product: CLVS1 Antibody
Catalog: DF15830
Description: Rabbit polyclonal antibody to CLVS1
Application: IHC IF/ICC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 41kD(Calculated).
Uniprot: Q8IUQ0

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
CLVS1 Antibody detects endogenous levels of CLVS1.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Cellular retinaldehyde binding protein like; CRALBPL; FLJ37248; Retinaldehyde binding protein 1 like 1; RLBP1L1;

Immunogens

Immunogen:

A synthesized peptide derived from human CLVS1.

Uniprot:

Q8IUQ0(CLVS1_HUMAN) >>Visit HPA database.

Gene(ID):
CLVS1(157807)
Expression:
Q8IUQ0 CLVS1_HUMAN:

Expressed mainly in the brain.

Sequence:
MGPVSLLPKYQKLNTWNGDLAKMTHLQAGLSPETIEKARLELNENPDVLHQDIQQVRDMIITRPDIGFLRTDDAFILRFLRARKFHQADAFRLLAQYFQYRQLNLDMFKNFKADDPGIKRALIDGFPGVLENRDHYGRKILLLFAANWDQSRNSFTDILRAILLSLEVLIEDPELQINGFILIIDWSNFSFKQASKLTPSILKLAIEGLQDSFPARFGGVHFVNQPWYIHALYTLIKPFLKDKTRKRIFLHGNNLNSLHQLIHPEFLPSEFGGTLPPYDMGTWARTLLGPDYSDENDYTHTSYNAMHVKHTSSNLERECSPKLMKRSQSVVEAGTLKHEEKGENENTQPLLALD

Research Backgrounds

Function:

Required for normal morphology of late endosomes and/or lysosomes in neurons (By similarity). Binds phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2).

Subcellular Location:

Golgi apparatus>trans-Golgi network membrane>Peripheral membrane protein. Cytoplasmic vesicle>Clathrin-coated vesicle. Early endosome membrane>Peripheral membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed mainly in the brain.

Subunit Structure:

Forms a complex with clathrin heavy chain and gamma-adaptin.

Family&Domains:

The CRAL-TRIO domain is required for targeting to the membrane and for binding PtdIns(3,5)P2.

References

1). Directing Differentiation of Pluripotent Stem Cells Toward Retinal Pigment Epithelium Lineage. Stem Cells Translational Medicine, 2017 [IF=6.0]

Application: IF/ICC    Species: human    Sample:

Figure 3 Stage 2: Generation of a mixed RPE population. (A): Two days’ postseeding, SHEF1 human embryonic stem cells were treated with Induction Medium 1 for 4 days, followed by Induction Medium 2 for 3 days. At day 9, cells were replated in Dulbecco's modified Eagle's medium (DMEM) KSR-XF alone (Control) or Induction Medium 3 (ActA) for 19 days. Quantitative polymerase chain reaction was used to measure expression of a panel of RPE markers. RPE generated by using spontaneous differentiation (Sp. RPE) were used for comparison (n = 3, ±SD). (B): Representative images showing immunocytochemistry for CRALBP and MERTK in cells derived by directed differentiation and cultured as in panel A. Dotted squares indicate the region that is magnified in the panels below. RPE generated by spontaneous differentiation were used for comparison. Images are captured at ×10 magnification. (C): Quantification of CRALBP immunocytochemistry at day 28 in which cells during stage 2 were treated with DMEM KSR-XF (Control) or Induction Medium 3 (ActA) for 3 days, 5 days, 10 days, or 19 days. For fewer than 19-day ActA treatments, DMEM KSR-XF was used for the remainder of the 19-day period. RPE derived by using spontaneous differentiation (Sp. RPE) were used for comparison (n = 3, ±SD). Abbreviations: ActA, Activin A; d, days; RPE, retinal pigment epithelium; Sp. RPE, spontaneous differentiation retinal pigment epithelium.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.